Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences

Executive Summary

Merck adds to its stagnating HIV portfolio with US approvals of doravirine and a three-drug combo including the NNRTI, but the combo’s potential may be limited due to inclusion of an older version of tenofovir.

You may also be interested in...



Merck & Co./Gilead Team To Take On ViiV In Long-Term HIV Treatment

The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.

Merck Positions MK-8591 As Backbone For HIV Treatment And Prophylaxis

First-in-class antiviral could be a potential backbone for combo regimens and entry into PrEP. New data releases at IAS highlight potential in both settings.

Keytruda Is King, But Merck Faces Questions About Business Development

Keytruda continues to break records on the strength of its efficacy in lung cancer, and shows no signs of slowing down. But analysts were intrigued by repeated mentions of business development during Merck’s third quarter earnings call.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123778

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel